Skip to main content
Skip to footer content
First Patient Dosed in Phase Ib/II Trial Evaluating Tiprelestat for Treatment of COVID-19
Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
Proteo Biotech AG becomes tiakis Biotech AG.
Move to a new and larger office in Kiel, Germany.
tiakis Biotech AG has partnered with Northway Biotech to scale up its production capabilities.
German Federal Ministry of Education and Research („BMBF“) selects tiakis Biotech AG to develop Tiprelestat as a potential therapeutic for COVID-19.
New anchor investor Elevat3 Capital joins tiakis Biotech AG.
We will gladly answer your questions.
Get in Contact
phone: +49 431 8888 462